If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksExperian Regulatory News (EXPN)

Share Price Information for Experian (EXPN)

Share Price is delayed by 15 minutes
Get Live Data
2,701.00    48.00 (1.81%)
Bid:
2,707.00
Ask:
2,708.00
Spread: 1.00 (0.037%)
Market Cap: £23.95b
EXPN Live PriceLast checked at - London Stock Exchange

Intraday Experian Share Chart

Directorate Change

21 Dec 2017 10:00

RNS Number : 0587A
Experian plc
21 December 2017
 

Experian plc

 

 

Directorate Change

 

 

21 December 2017 - Experian, the global information services company, announces the appointment of a new independent Non-Executive Director to the Board of Experian plc, effective from 1 April 2018.

 

Dr. Ruba Borno, 36, a US national, is a member of the Executive Leadership Team at Cisco, the worldwide technology leader delivering solutions to help securely connect digital business. In her role at Cisco, she helps guide strategy and leads priority initiatives across key partnerships, technology and investment strategies. Ruba is central to informing Cisco's digital and business transformation and that of its customers and partners.

 

Holding a Ph.D. and a Master of Science in Electrical Engineering, and a Bachelor of Science in Computer Engineering, Ruba was an Intel Ph.D. fellow at the National Science Foundation's Engineering Research Center for Wireless Integrated MicroSystems. She sits on the board of The Tech Museum of Innovation in Silicon Valley. Ruba was previously at The Boston Consulting Group (BCG) where she specialised in helping enterprises through complex technology transformations, and was a leader in BCG's Technology, Media & Telecommunications, and People & Organization practice groups.

 

Don Robert, Chairman of Experian, commented:

 

"I am very pleased to welcome Ruba Borno to the Board of Experian. Ruba will bring advanced technologies expertise, and the Board and Experian will also benefit greatly from her focus on supporting businesses in strategically adapting to the threats and opportunities created by technology, as well as pushing disruptive technology to create new opportunities. We will also benefit from her insight and understanding of digitisation and technology transformation across industries."

 

The Company confirms that there are no details to be disclosed under Listing Rule 9.6.13R, paragraphs (1) to (6).

 

Contacts

 

Experian

Nadia Ridout-Jamieson Investor queries +44 (0)20 3042 4215

Gerry Tschopp Media queries

 

Finsbury

Rollo Head +44 (0)20 7251 3801

Jenny Davey

 

About Experian

Experian is the world's leading global information services company. During life's big moments - from buying a home or a car, to sending a child to college, to growing a business by connecting with new customers - we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organisations to prevent identity fraud and crime.

 

We have 16,000 people operating across 37 countries and every day we're investing in new technologies, talented people and innovation to help all our clients maximise every opportunity. We are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.

 

Learn more at www.experianplc.com or visit our global content hub at our global news blog for the latest news and insights from the Group.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATBBLTMBTTMAR
Date   Source Headline
12th Apr 20239:30 amRNSAdditional Listing
4th Apr 20239:45 amRNSAdditional Listing
31st Mar 202311:35 amRNSTotal Voting Rights
29th Mar 20239:20 amRNSAdditional Listing
28th Mar 20237:00 amRNSDirectorate Change
22nd Mar 20235:19 pmRNSTransaction in Own Shares
22nd Mar 20239:15 amRNSAdditional Listing
20th Mar 20235:18 pmRNSTransaction in Own Shares
17th Mar 20235:31 pmRNSTransaction in Own Shares
16th Mar 20235:09 pmRNSTransaction in Own Shares
16th Mar 20239:15 amRNSBlock listing Interim Review
15th Mar 20235:14 pmRNSTransaction in Own Shares
15th Mar 20239:15 amRNSAdditional Listing
14th Mar 20235:21 pmRNSTransaction in Own Shares
13th Mar 20235:31 pmRNSTransaction in Own Shares
10th Mar 20236:10 pmRNSTransaction in Own Shares
9th Mar 20235:22 pmRNSTransaction in Own Shares
8th Mar 20235:21 pmRNSTransaction in Own Shares
8th Mar 20239:15 amRNSAdditional Listing
7th Mar 20235:26 pmRNSTransaction in Own Shares
1st Mar 202312:00 pmRNSDirector/PDMR Shareholding
1st Mar 20239:15 amRNSAdditional Listing
28th Feb 202312:20 pmRNSTotal Voting Rights
22nd Feb 202310:00 amRNSAdditional Listing
15th Feb 202310:45 amRNSAdditional Listing
10th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20239:30 amRNSAdditional Listing
1st Feb 20239:15 amRNSAdditional Listing
31st Jan 20232:30 pmRNSDirector Declaration
31st Jan 202310:15 amRNSTotal Voting Rights
25th Jan 20239:15 amRNSAdditional Listing
17th Jan 20237:00 amRNSExperian Q3 FY23 trading update
13th Jan 20235:20 pmRNSFirst interim dividend
9th Jan 20237:00 amRNSDirectorate Change
30th Dec 202210:15 amRNSTotal Voting Rights
16th Dec 202211:30 amRNSElections for first interim dividend
14th Dec 20229:15 amRNSAdditional Listing
7th Dec 20229:00 amRNSAdditional Listing
30th Nov 202211:59 amRNSTotal Voting Rights
16th Nov 20227:00 amRNSHalf-year Report
31st Oct 20229:30 amRNSTotal Voting Rights
14th Oct 20229:51 amRNSShare Repurchase Programme
6th Oct 20227:00 amRNSDirectorate Change
5th Oct 20229:10 amRNSAdditional Listing
30th Sep 202212:06 pmRNSTotal Voting Rights
28th Sep 20229:02 amRNSAdditional Listing
19th Sep 202210:00 amRNSBlock listing Interim Review
14th Sep 20229:30 amRNSAdditional Listing
7th Sep 20229:30 amRNSAdditional Listing
31st Aug 202210:07 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.